Sonoma Pharmaceuticals (SNOA) Other Operating Expenses (2015 - 2026)
Sonoma Pharmaceuticals' (SNOA) quarterly Other Operating Expenses came in at -$146000.0 in Q1 2026, down 214.06% year-on-year from $128000.0 in Q1 2025, and up 46.13% quarter-over-quarter from -$271000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Other Operating Expenses (2015 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Other Operating Expenses history runs 12 years deep, the most recent figure standing at -$146000.0 for Q1 2026.
- On a quarterly basis, Other Operating Expenses fell 214.06% year-over-year to -$146000.0 in Q1 2026; TTM through Mar 2026 was -$958000.0, a 219.3% decrease from a year earlier, with the FY2026 full-year figure at -$958000.0, down 219.3% from the prior year.
- Other Operating Expenses grew to -$146000.0 in Q1 2026 per SNOA's latest filing, from -$271000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $387000.0 in Q3 2024 and bottomed at -$544000.0 in Q1 2022.
- The 5-year median for Other Operating Expenses is -$90000.0 (2023), against an average of -$96764.7.
- Across the five-year window, Other Operating Expenses tumbled 745.45% in 2022 and soared 530.0% in 2024, its largest moves.
- Year by year, Other Operating Expenses stood at -$71000.0 in 2022, then decreased by 11.27% to -$79000.0 in 2023, then soared by 241.77% to $112000.0 in 2024, then slumped by 341.96% to -$271000.0 in 2025, then soared by 46.13% to -$146000.0 in 2026.
- Per Business Quant, the three latest SNOA Other Operating Expenses figures stand at -$146000.0 (Q1 2026), -$271000.0 (Q4 2025), and -$394000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Sonoma Pharmaceuticals | 179.80 | -2.40 Mn | 2.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -146,000.00 |
| Dec 31, 2025 | -271,000.00 |
| Sep 30, 2025 | -394,000.00 |
| Jun 30, 2025 | -147,000.00 |
| Mar 31, 2025 | 128,000.00 |
| Dec 31, 2024 | 112,000.00 |
| Sep 30, 2024 | 387,000.00 |
| Jun 30, 2024 | 176,000.00 |
| Mar 31, 2024 | 50,000.00 |
| Dec 31, 2023 | -79,000.00 |
| Sep 30, 2023 | -90,000.00 |
| Jun 30, 2023 | -211,000.00 |
| Mar 31, 2023 | -292,000.00 |
| Dec 31, 2022 | -71,000.00 |
| Sep 30, 2022 | -186,000.00 |
| Jun 30, 2022 | -67,000.00 |
| Mar 31, 2022 | -544,000.00 |
| Dec 31, 2021 | 11,000.00 |
| Sep 30, 2021 | 723,000.00 |
| Jun 30, 2021 | -193,000.00 |